Zacks Research Has Bearish Forecast for Sanofi Q3 Earnings

Sanofi (NASDAQ:SNY) – Zacks Research decreased their Q3 2025 EPS estimates for shares of Sanofi in a report issued on Wednesday, March 5th. Zacks Research analyst K. Shah now expects that the company will post earnings of $1.57 per share for the quarter, down from their prior estimate of $1.59. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Sanofi’s Q2 2026 earnings at $1.00 EPS and FY2027 earnings at $4.75 EPS.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%.

A number of other research firms have also recently commented on SNY. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $60.00.

Sanofi Price Performance

Shares of SNY opened at $59.25 on Monday. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $59.72. The firm’s 50-day simple moving average is $52.65 and its two-hundred day simple moving average is $52.73. The stock has a market cap of $150.37 billion, a PE ratio of 23.80, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its stake in shares of Sanofi by 31.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock worth $8,040,000 after acquiring an additional 33,105 shares during the last quarter. Arkadios Wealth Advisors lifted its holdings in Sanofi by 19.0% during the fourth quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock valued at $227,000 after purchasing an additional 751 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Sanofi by 7.1% in the 3rd quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock worth $14,681,000 after buying an additional 16,780 shares during the period. JPMorgan Chase & Co. raised its holdings in Sanofi by 20.9% during the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after acquiring an additional 399,301 shares during the period. Finally, Kentucky Trust Co purchased a new position in shares of Sanofi in the fourth quarter valued at about $436,000. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.